Multi-index joint detection feasibility study for hepatocacinoma screening

doi:10.3877/cma.j.issn.1674-0793.2016.04.015

Abstract

Abstract:

Objective

To explore the feasibility of multi-index joint detection of hepatitis B surface antigen (HBsAg), Anti-hepatitis C virus (Anti-HCV), HBV-DNA and alpha-fetoprotein (AFP) for screening liver cancer.

Methods

From May 2014 to October 2015, one hundred and thirty-nine cases with hepatocellular carcinoma in Zhongshan People's Hospital were selected as case group. At the same time, 556 cases were chosen as control group by age±5 and gender in the ratio of 4:1 randomly matched group cases in Zhongshan Gity liver cancer screening research in 2012. HBsAg, Anti-HCV and AFP in serum were detected by enzyme-linked immunosorbent assay (ELISA). FQ-PCR method was used to detect HBV-DNA in serum samples. Positive rate of single index indicators in the two groups, and the sensitivity, specificity, and false negative rate of multiple-index combined detection were explored in hepatocarcinoma screening.

Results

AFP sensitivity was the best for single index screening, followed by HBsAg. When HBsAg was used as the main body of the combined screening, the combination of different indicators had different sensitivity, with the miss rate of HBsAg, Anti-HCV, and AFP joined by HBV-DNA having the best sensitivity and the lowest miss rate; followed by HBsAg, AFP joined by HBV-DNA; and by HBsAg, Anti-HCV joined by AFP.

Conclusion

Combined detection of HBsAg, Anti-HCV and AFP screening can improve the early screening effect of high-risk liver cancer patients.

Key words: Liver neoplasms, Early detection of cancer, Hepatitis B virus, Hepatitis C antibodies, Alpha-fetoproteins

Hao Sun, Mingfang Ji, Changhua Zhang, Zemin Hu, Qianjin Feng, Yuanlong Yu. Multi-index joint detection feasibility study for hepatocacinoma screening[J]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(04): 294-297.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2016.04.015

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2016/V10/I04/294

Figures/Tables 4

References 17

1	余元龙,魏矿荣,季明芳,等.中山市恶性肿瘤发病地域分布研究[M].中山:广东人民出版社, 2012.
2	梁智恒,彭侠彪,岑惠珊,等.广东省中山市1970~2010年肝癌发病概况[J].中国肿瘤, 2015, 24(8): 631-637.
3	梁智恒,彭侠彪,岑惠珊,等.广东省中山市1970~2010年肝癌死亡概况[J].中国肿瘤, 2015, 24(8): 638-644.
4	Flores A,Marrero JA. Emerging trends in hepatocellular carcino-ma: focus on diagnosis and therapeutics[J]. Clin Med Insights On-col, 2014, 8: 71-76.
5	Abe K,Edamoto Y,Park YN, et al. In situ detection of hepatitis B, C, and G virus nucleic acids in human hepatocellular carcinoma tissues from different geographic regions[J]. Hepatology, 1998, 28(2): 568-572.
6	Hall AJ,Wild CP. Liver cancer in low and middle income coun-tries[J]. BMJ, 2003, 326(7397): 994-995.
7	Wong RJ,Waknuk J,Valenzuela A, et al. Primary surgical resec-tion versus liver transplantation for transplant eligible hepatocel-lular carcinoma patients[J]. Dig Dis Sic, 2014, 59(1): 183-191.
8	Lencioni R,Cioni D,Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percuta-neous image-guided radio frequency ablation [J]. Radiology, 2005, 234(3): 961-967.
9	Llovet JM. Updated treatment approach to hepatocellular carcino-ma[J]. Gastroenterology, 2005, 40(3): 225-235.
10	癌症早诊早治项目专家委员会.癌症早诊早治项目技术方案(2011年版)[M].北京:人民卫生出版社, 2011: 110-143.
11	俞霞,季明芳,程伟民,等.中山市小榄镇肝癌高发现场筛查评估及问题分析[J].肿瘤防治研究, 2016, 43(4): 287-290.
12	姜世强,柳青. Logistic回归模型在早期鼻咽癌多指标联合辅助诊断实验的应用[J].癌症, 2009, 28(2): 213-216.
13	Barve A,Khan R,Marsano L, et al. Treatment of alcoholic liver disease[J]. Ann Hepatol, 2008, 7(1): 5-15.
14	Fan JG,Zhu J,Li XJ, et al. Prevalence of and risk factors for fat-ty liver in a general population of Shanghai, China[J]. J Hepatol, 2005, 43(3): 508-514.
15	Tateishi R,Yoshida H,Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic re-view[J]. Hepatol Int, 2008, 2(1): 17-30.
16	Thomson SJ,Westlake S,Rahman TM, et al. Chronic liver disease-an increasing problem: a study of hospital admission and mortality rates in England, 1979-2005, with particular reference to alcohol-ic liver disease[J]. Alcohol Alcohol, 2008, 43(4): 416-422.
17	Shim J,Kim BH,Kim NH, et al. Clinical features of HBsAg-neg-ative but anti-HBc-positive hepatocellular carcinoma in a hepati-tis B virus endemic area[J]. J Gastroenterol Hepatol, 2005, 20(5): 746-751.

组别	例（人）	HBsAg	Anti-HCV	HBV-DNA	AFP
病例组	139	89(64.03)	6(4.32)	84(60.43)	91(65.47)
对照组	556	93(16.73)	2(0.36)	10(1.80)	9(1.62)
χ²值	?	128.72	15.30	326.86	368.01
P值	?	<0.01	<0.01	<0.01	<0.01

组别	例（人）	HBsAg	Anti-HCV	HBV-DNA	AFP
病例组	139	89(64.03)	6(4.32)	84(60.43)	91(65.47)
对照组	556	93(16.73)	2(0.36)	10(1.80)	9(1.62)
χ²值	?	128.72	15.30	326.86	368.01
P值	?	<0.01	<0.01	<0.01	<0.01

指标	敏感度(%)	特异度(%)	约登指数	漏检率(%)
HBsAg	64.03	83.27	0.473 0	35.97
Anti-HCV	4.32	99.64	0.039 6	95.68
HBV-DNA	60.43	98.20	0.586 3	39.57
AFP	65.47	98.38	0.638 5	34.53

指标	敏感度(%)	特异度(%)	约登指数	漏检率(%)
HBsAg	64.03	83.27	0.473 0	35.97
Anti-HCV	4.32	99.64	0.039 6	95.68
HBV-DNA	60.43	98.20	0.586 3	39.57
AFP	65.47	98.38	0.638 5	34.53

组别	例（人）	Anti-HCV	HBV-DNA	AFP
病例组	50	5(10.00)	14(28.00)	15(30.00)
对照组	463	2(0.43)	8(1.73)	9(1.94)
χ²值	?	30.70	79.65	75.89
P值	?	<0.01	<0.01	<0.01

Please choose a citation manager

Content to export